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THE ELECTROCHEMICAL PROTON GRADIENT (the proton mo-tive force, p =  + pH) between the intermembrane
space and the matrix of mitochondria is produced by the elec-
tron transport chain residing in the mitochondrial inner mem-
brane (Fig. 1). As first proposed by Mitchell (61), this gradi-
ent is now known to be the driving force for ATP synthesis,
called “coupling.” Many proteins, including members of the
mitochondrial carrier family, harness p for their function,
some using its electrical component (ADP/ATP carrier and
glutamate/aspartate carrier) and others using the pH gradi-
ent (phosphate carrier and other carriers using substrate-H+
symport). Any process using p without ATP synthesis has
been termed “uncoupling.” Uncoupling protein 1 (UCP1; ther-
mogenin) was first recognized as the protein-mediated un-
coupling activity in brown adipose tissues (BAT), in which
it acts as the non-shivering heat generator to maintain the
body temperature in newborns and hibernating mammals (9,
47, 64).
A number of other protein members of the SLC25 sub-
family of the mitochondrial transporter superfamily (for re-
view, see 67) have been designated as “uncoupling proteins”
(UCPs) based initially on their sequence homology with
UCP1 and evidence that they had many of the same func-
tional motifs. Of those studied to date, all appear to be lo-
cated in the inner mitochondrial membrane and to uncouple
the proton gradient. More than 45 genes encoding UCP iso-
forms have been described in single-cell organisms, plants,
and animals, including humans (54). In addition to UCP1,
many of these additional UCP isoforms have been cloned
from plants and mammals, and their physiological roles have
begun to be investigated (8). UCPs are expressed in a tissue-
specific manner, suggesting distinct roles and regulation of
their function in different locations. UCP2 has broad tissue
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ABSTRACT
Mitochondrial uncoupling proteins (UCPs), a subfamily of the mitochondrial transporter family, are related
by sequence homology to UCP1. This protein, which is located in the inner mitochondrial membrane, dissi-
pates the proton gradient between the intermembrane space and the mitochondrial matrix to uncouple elec-
tron transport from ATP synthesis. UCP1 (thermogenin) was first discovered in brown adipose tissue and
is responsible for non-shivering thermogenesis. Expression of mRNA for three other UCP isoforms, UCP2,
UCP4, and BMCP1/UCP5, has been found at high levels in brain. However, the physiological function(s) of
UCPs in the brain have not been determined, although it has recently been postulated that UCPs regulate
free radical flux from mitochondria by physiologically modulating mitochondrial membrane potential. In the
CNS, this hypothesis has been studied primarily for UCP2. UCP2 message has been shown to be up-regulated
in the CNS by stress signals such as kainate administration or ischemia, and overexpression of UCP2 has been
reported to be neuroprotective against oxidative stress in vivo and in vitro, although the exact mechanism has
not been fully established. In this review, studies on UCPs in the nervous system will be reviewed, and the po-
tential roles of these intriguing proteins in acute and chronic diseases of the nervous system will be discussed.
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expression, whereas UCP1 is almost exclusively expressed
in BAT, and UCP3 is found mainly in BAT and skeletal mus-
cle. UCP2 and UCP3 have the highest degree of homology
to UCP1. Although they have significantly lower degrees
of homology to UCP1, UCP4 and BMCP1/UCP5 have been
added as putative members of the UCP family because
they show most of the functional motifs of UCP1. Another
isoform, SLC25A30, was recently reported by the RIKEN
cDNA library to have a high degree of sequence homology to
BMCP1/UCP5, but has not yet been studied. In BAT, UCP1
is highly expressed as one of the major mitochondrial pro-
teins and, when activated, results in sufficient heat genera-
tion to maintain body temperature in newborns. Evidence
suggests that UCP2 is not important for thermogenesis, how-
ever (2, 87). All UCPs are expressed at significantly lower
levels in their respective tissues compared with UCP1 in
BAT, suggesting that the function of these UCP isoforms
may not be thermogenesis. The observation that the newer
UCPs are expressed at such low levels prompted introduc-
tion of the concept of “mild uncoupling” (76)—in which
functional regulation of mitochondrial reactive oxygen
species (ROS) production occurs through modest decreases
in m—for the non-UCP1 family members (Fig. 1). Mito-
chondria are considered to be one of the main sources for in-
tracellular ROS, and the mitochondrial membrane potential
is the driving force for ROS generation as well as ATP produc-
tion. A small decrease in m can dramatically reduce pro-
duction of ROS, specifically hydrogen peroxide (H2O2) (49).
In addition, this mild uncoupling activity has been proposed
to be one of the key modulators of cellular metabolism and
signal transduction through regulation of mitochondrial ROS
production (11, 32), because many critical signaling path-
ways have redox-sensitive components (30, 31). As the in-
volvement of mitochondrial ROS dysregulation in neurode-
generative diseases has been a focus of research for many
decades, and altered production or decomposition of ROS
has been observed in many experimental models of CNS in-
jury and neurodegenerative diseases, the possibility that UCPs,
by regulating mitochondrial ROS levels, could be important
modifiers of CNS damage has recently emerged. In this review,
the involvement of UCPs in regulation of ROS will be
1174 KIM-HAN AND DUGAN
described, and the physiological and pathological roles of
UCPs in the nervous system will be discussed.
UCP EXPRESSION: TRANSCRIPTIONALAND
POSTTRANSCRIPTIONAL REGULATION
Although regulation of UCP gene expression at the
mRNA level has been demonstrated in response to a diverse
range of stimuli, including exposure to cold, high fat and ke-
togenic diets, starvation, leptin, insulin, inflammatory cyto-
kines, and endotoxin (for review, see 14), regulation of pro-
tein is rarely reported. In part, this reflects problems with
currently available UCP antibodies, including both custom-
prepared and commercially available antibodies. Most are not
exclusively specific to each isoform (69), and we have found
that several antibodies detect 32–36-kDa bands in various
knockout mice (Dugan and Kim-Han, unpublished observa-
tions), suggesting that specific, well characterized antibodies
would be extremely useful reagents for future studies on the
UCPs.
Regulation of UCP mRNA has not, in many cases, been
followed by changes in UCP protein expression (43, 75),
suggesting posttranscriptional regulation of UCP expression
(23, 69). Recently, message for UCP2 has been found with-
out concomitant protein expression (84). This disconnect
between mRNA and protein expression results from an up-
stream AUG stop codon and alternative open reading frames
(ORFs) in the 5-untranslated region as a key determinant of
posttranscriptional regulation (69). One or three upstream
ORFs have been identified in UCP2/3 and BMCP1/UCP5, re-
spectively, and these result in dramatically reduced efficiency
of translation (Fig. 2). In addition, more than six mRNA
splicing variants have been detected for BMCP1/UCP5
mRNA (Dugan and Kim-Han, unpublished observations).
We have also experienced inhibition of UCP expression after
in vitro transfection in mammalian cells, although mRNA
was clearly present (Dugan and Kim-Han, unpublished obser-
vations). Other posttranscriptional mechanisms, including
changes in mRNA stability, need to be studied for these pro-
 
 
FIG. 1. Effect of UCP on the production of ROS. (A) Under normal conditions, the proton gradient established by the elec-
tron transport chain (ETC) is coupled to ATP synthesis through F1F0-ATPase. When the membrane is highly polarized, electron
transfer from the ETC to oxygen is enhanced, increasing levels of ROS (superoxide, H2O2). In the presence of purine nucleotides
(GDP), UCP activity is inhibited and elevated membrane potential and ROS production are maintained. (B) When overexpression
of UCP or activation of the protein occurs, e.g., by binding of free fatty acids (FFA) or coenzyme Q10, the proton gradient is
brought below the critical point for ROS production, and mitochondrial ROS formation decreases.
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teins. In summary, it is important to bear in mind that the reg-
ulation of UCP mRNA expression may not correspond to that
of protein expression, and that mRNA data as predictive of
UCP protein or activity should be interpreted with some de-
gree of caution.
REGULATION OF UCP ACTIVITY
Well known regulators of UCP activity are free fatty acids
and purine nucleotides. Polyunsaturated fatty acids activate
UCP, whereas bovine serum albumin, a fatty acid binding
protein, inhibits UCP activity (25, 47). The purine nucleo-
tides, ADP and GDP, also inhibit the proton conductance
induced by various stimuli in vitro by binding to a specific
allosteric site. The specificity and preference of a given UCP
isoform for specific free fatty acid species has not been fully
defined, but would be of interest because different fatty acid
pools are released by varying stimuli, including ischemia and
traumatic injury (1, 4, 36, 52, 53, 70, 79). In addition, there
remains a controversy about whether free fatty acids are not
only “activators” of UCP activity through a specific, high-
affinity binding site, but “transported substrates” of UCPs,
being cotransported with protons under selected circum-
stances (34). This alternative fatty acid transport activity has
been most convincingly shown to date for UCP1 and UCP3.
Regardless of their mechanisms of action, the requirement for
nanomolar to micromolar concentrations of free fatty acids
for full UCP activation has been well established (25, 35).
It was recently demonstrated that specific free radicals and
oxidized macromolecules can modify the activity of UCPs.
Echtay et al. reported that superoxide increases mitochon-
drial proton conductance through UCPs (26). This superoxide-
mediated increase in conductance was sensitive to GDP and
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required fatty acids. Superoxide-stimulated proton conduc-
tance through UCPs was reversible, pH-dependent, and sensi-
tive to superoxide dismutase (SOD), but not to catalase (26).
Breakdown products of lipid peroxidation, such as 4-hydrox-
ynonenal and its related compounds, specifically induce pro-
ton conductance of mitochondria through the uncoupling pro-
teins (UCP1, UCP2, and UCP3) and the adenine nucleotide
translocase in animals (27) and through StUCP (UCP homo-
logue in Solanum tuberosum) in plants (77). Moreover, prod-
ucts of lipid peroxidation, such as cleaved hydroperoxy-fatty
acids and hydroxy-fatty acids, have been reported to activate
UCP2 and promote feedback down-regulation of mitochon-
drial ROS production (10).
Endogenously produced superoxide also increases proton
conductance through activation of UCP3 in skeletal muscle,
subsequently limiting mitochondrial production of super-
oxide (82). Recently, Krauss and colleagues reported UCP2
activation by superoxide introduced exogenously using mito-
chondria from kidney and spleen (50). Exogenously gener-
ated superoxide also activated UCP2 in thymocytes and B
cells in mice, and activation was inhibited by MnTBAP, a
SOD mimetic, or manganese superoxide dismutase (MnSOD),
but not by glutathione peroxidase (GPX1). Although UCP ac-
tivation by superoxide was absent in UCP2 knockout (KO)
mice, implying that UCP2 may be activated by superoxide, in
another study (18), UCP2 was clearly not activated by super-
oxide. As other UCP isoforms, specifically UCP1 (26) and
UCP3 (26, 82), can be activated by superoxide, the expres-
sion of other UCPs in UCP2 KO mice should be determined
to verify that other UCPs were not induced as has been shown
previously (19). Specific activation of UCPs by superoxide
also needs to be further confirmed by comparison with other
inner mitochondrial membrane proteins. In addition, Li and
colleagues pointed out that the superoxide-generating system,
xanthine oxidase metabolism of xanthine, used for some of
FIG. 2. The putative ORFs at the upstream of the starting codon in mouse UCP mRNAs. Among UCPs, UCP1 does not
have any putative ORF. UCP2 and UCP5/BMCP1 have three ATG codons at the upstream of the starting codon with one and three
ORFs, respectively. Rat UCP4 mRNA has an ORF found in the 5-untranslated region. Slc25a30 is highly homologous to UCP5/
BMCP1. (M, ATG codon. The size of mRNA is shown in the box at the right side.)
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these studies, consumes oxygen to produce superoxide, thus
reducing oxygen content in the reaction mixture and modify-
ing mitochondrial respiratory studies (56). Experiments using
an in vitro reconstituted system might give more direct an-
swers to this controversial question.
Ubiquinone has also been reported to be an activator of
UCP1 (24). Short-term oral administration of ubiquinone in-
duced nigral mitochondrial uncoupling and prevented dopa-
mine cell loss after 1-methyl-4-phenyl-1,2,5,6-tetrahydropy-
ridine administration in monkeys (41), although whether the
effects of ubiquinone were due to activation of a UCP iso-
form, or to the multiple other actions (e.g. antioxidant) of this
electron transport chain component, are not yet established.
The requirement of ubiquinone for UCP activation has not
been clearly demonstrated in other model systems, such as
yeast and reconstituted liposomes (29, 42), so this remains an
important area of UCP research.
Information regarding the regulation of UCP activity is
likely to be more relevant than that of expression of UCP
mRNA or protein per se. Why? With the exception of UCP1,
expression of other UCP isoforms appears to be quite low, at
least two orders of magnitude lower than that of UCP1, mea-
sured by [3H]GDP binding (86). Furthermore, even in BAT,
with its high content of UCP1, it is only after activation of
UCP1 by fatty acids that uncoupling and thermogenesis can
be detected, indicating that the presence of protein will not
necessarily predict uncoupling activity. Experiments per-
formed to determine UCP activity have generally been per-
formed with isolated mitochondria from tissues that express
mixed pools of UCPs, as well as other mitochondrial carrier
proteins which may contribute to a small extent to “uncou-
pling” activity. Many studies using tissues and transfected
cells have assigned uncoupling activity to a specific UCP
without knowing the isoforms present in their systems. The
contribution of one individual UCP in such preparations and
the degree to which mitochondria “compensate” for the absence
or overexpression of a single UCP remain an open question.
Finally, the UCP expression profile in a given experimental
model may differ from that reported in the literature. It is
clear that there are strain differences in UCP expression even
at baseline, and there are differing responses reported for the
same treatment in different strains (37, 81).
MODULATION OF MITOCHONDRIAL
ROS PRODUCTION BY UCPs
One of the main sites for intracellular ROS formation is
the mitochondrial electron transport chain, in which super-
oxide is generated as a by-product of electron transport. In
isolated mitochondria, inhibitors of complex I and III signifi-
cantly increase the production of ROS (10, 13, 15). Produc-
tion is closely dependent on mitochondrial membrane poten-
tial, i.e., a small increase in m can cause a robust production
of superoxide and H2O2. A 10% decrease in m resulted in a
55% decrease in H2O2 production (49). A 10-mV decrease in
m reduced superoxide production up to 70% by complex I
following reverse electron flow from glycerol 3-phosphate
(62). Physiological activation of UCPs has therefore been
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proposed to decrease ROS production. Although UCPs act as
uncouplers, because of their low level of expression and the
requirement for small-molecule activators for UCPs to be
fully activated, the contribution of UCPs to regulation of m
is likely to be quite small, leading to the previously-mentioned
concept of “mild uncoupling” (62, 76). This concept explains
why there are no significant changes in basal levels of proton
conductance in either UCP-overexpressing or KO animals until
nonphysiological conditions are present. The role of UCPs in
regulating ROS was first reported in 1997. In this study, GDP,
an inhibitor of UCPs, increased both m and production of
H2O2 in mitochondria from BAT and liver (63). Macrophages
from UCP2 KO mice produce more ROS, increasing their re-
sistance to toxoplasmosis infection (2). Antisense treatment
to decrease UCP2 expression increased ROS production and
lipid peroxidation in murine endothelial cells (22). Mitochon-
drial H2O2 production is lowered by calorie restriction, and
this appears to involve up-regulation of UCP3 in rat muscle
mitochondria (7). Glucose-induced ROS production through
early mitochondrial hyperpolarization was inhibited by UCP3
and UCP1 overexpression in dorsal root ganglia (DRG) neu-
rons (83). In brain mitochondria, UCP2 overexpression also
reduced mitochondrial ROS content, determined by flow cy-
tometry using dichlorofluorescein fluorescence (59, 63, 66).
Taken together, UCPs modulate ROS production possibly
through decreasing mitochondrial membrane potential.
EXPRESSION AND FUNCTION
OF UCPs IN BRAIN
Message for three UCP isoforms, UCP2, UCP4, and
BMCP1/UCP5, has been found in brain. UCP2 mRNA is
ubiquitously expressed in various tissues, including brain in
rodents (38, 72), and is mainly neuronal, although there is
some debate about whether UCP2 protein is expressed pre-
dominantly in macrophages under basal conditions (73).
UCP4 message is exclusively in brain (58), whereas BMCP1/
UCP5 is expressed in brain and several other tissues, includ-
ing heart and kidney (45, 48, 74). Although no expression of
UCP1 or UCP3 mRNA has been reported for brain, recently,
UCP3 protein was found in rat DRG neurons immediately after
dissection, but not in cultured DRG neurons (83). The authors
suggested that UCP3 was protective against glucose-induced
neuronal death in DRG neurons. Carefully performed quan-
titative RT-PCR analysis to determine the expression of
UCPs in brain cortex indicated the following order: UCP5 >
UCP4 > UCP2 >>> UCP3, UCP1 (55). Recently, expression
of an isoform of BMCP1/UCP5 in fruit flies was also found
predominantly in the head of adult flies (33), supporting an
important role for this putative UCP in the CNS. The amount
of overall UCP protein, shown by [3H]GTP binding in brain,
has been reported to be substantially lower than in BAT or
spleen, but higher than in kidney, skeletal muscle, or liver
(44). Despite the presence of at least three isoforms of UCP
in brain, UCP2 has been the focus of the majority of studies
on brain injury and neurodegenerative diseases. In normal
brain, UCP2 mRNA expression is localized to specific brain
regions, whereas in pathological conditions, UCP2 mRNA is
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up-regulated in the regions affected by the injury. UCP2
mRNA is induced by transient ischemia in lesioned entorhi-
nal cortex (5, 57) and in the periinfarct area in the neocortex
and caudate putamen after 3–4 days (19). Both sublethal isch-
emia (59) and chemically induced seizures (21) increase
mRNA expression in mouse hippocampus. Kainic acid (KA),
given by intraperitoneal injection to mice, also induced UCP2
mRNA in the CA1 subfield of the hippocampus, the dorsal
endopiriform nucleus, and the piriform cortex, areas sensitive
to KA excitotoxity (6, 51). Induction was primarily neuronal
and reached a maximum at 24 h, returning to basal levels
within 72 h post injection. This neuronal induction of UCP2
mRNA by KA was more extensive in 129T2SvEmsJ, a KA-
sensitive mouse strain, than in C57BL/6J, a KA-insensitive
one, suggesting a specific link between UCP2 in KA excito-
toxicity (17). Lipopolysaccharide, a commonly-used activator
of oxidative stress, induced UCP2 mRNA, but not BMCP1/
UCP5 mRNA in mice (12). Administration of a ketogenic diet
increased mitochondrial respiration by fatty acids, possibly
through induction of one or more uncoupling proteins (80).
It has been postulated that ROS generation is one of the
main factors for both neurodegeneration and aging, so UCP-
dependent reduction of ROS in the nervous system has the
potential to be neuroprotective in age-related neurodegenera-
tive diseases, as well (28, 46).
Although UCP4 and BMCP1/UCP5 have sequence homol-
ogy to UCP1, and UCP2–3 (29–34% and 34–39%, respec-
tively) and show uncoupling activity in in vitro systems
(58, 74), their function in brain has yet to be established.
BMCP1/UCP5 mRNA was down-regulated by hypoxia and
up-regulated by oxidative stressors, such as hyperoxia, 4-hy-
droxynonenal, or tert-butyl hydroperoxide in SH-SY5Y neu-
roblastoma cells (71). BMCP1/UCP5 message was decreased
by chronic hypoxia and increased by transient global cerebral
ischemia in rats (71), but was unaltered by cerebral ischemia
in adult (19) and neonatal (Kim-Han, Reichert, and Dugan,
unpublished observations) mice.
Among the three main isoforms of UCP expressed in brain,
UCP2 is the most well characterized. UCP2 appears to reduce
ROS production in brain under pathological, but not physio-
logical, conditions. Focal cerebral ischemia produced by mid-
dle cerebral artery occlusion (MCAO) was used to test the role
of UCP2 in CNS injury using both UCP2 transgenic and
UCP2 KO mice. Both overexpressing and KO mice were resis-
tant to ischemic injury (19, 59). Overexpression of UCP2/3
was neuroprotective against MCAO in vivo and oxygen-glu-
cose deprivation in vitro. Levels of ROS in the mitochondrial
matrix were lower in mitochondria from UCP2/3 transgenic
mice than from nontransgenic controls, although there was no
difference in total production of ROS (59, 68). In response to
MCAO, UCP2 KO mice also showed a smaller infarct volume,
less TUNEL-positive cells, no cytochrome c translocation,
and less lipid peroxidation products compared with the control
mice. The paradox that both overexpression and targeted dele-
tion of UCP2 were neuroprotective has been explained by the
observation that UCP2 KO mice show higher expression of
MnSOD and had higher mitochondrial [GSH] than wild-type
mice. Like the dicarboxylate and 2-oxoglutarate carriers (16),
UCP2 may regulate mitochondrial GSH uptake. As UCP2 KO
mice are presumed to produce more mitochondrial ROS, up-
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regulation of MnSOD and lowered consumption of GSH
after ischemia have been proposed as compensatory mecha-
nisms (19). These reports suggested that UCP2 can modify
mitochondrial antioxidant defense systems. Overexpression of
UCP2 also resulted in neuroprotection and lower caspase-3
immunoreactivity after entorhinal cortex lesioning (5) and
was protective against oxidative stress-induced cell death in
PC12 cells (21). Although UCP2 overexpression does not
prevent seizures after scopolamine/pilocarpine treatment, it
reduced cell death after the seizures (21). On the other hand,
overexpression of UCP2 may cause cells to have difficulty
providing enough ATP production for cellular metabolism,
leading to mitochondrial biogenesis to support ATP produc-
tion (40). In fact, UCP2 overexpression increased mitochon-
drial number, presumably to compensate for decreased ATP
production by uncoupled mitochondria (21). In addition,
UCP2 negatively regulates secretion of insulin (87) and do-
pamine (85) through an ATP-dependent process. How these
effects factor into neuroprotection or neurodegeneration has
not yet been determined, and may be complex.
Ethanol sensitivity was decreased in UCP2-overexpress-
ing mice and increased in UCP2 KO mice. UCP2 also modi-
fied the impairment of pain and temperature sensation in-
duced by ethanol, which is consistent with localization of
UCP2 in primary sensory afferents of the spinal cord (38).
Overexpression of UCP1 or UCP3 is also neuroprotective in
glucose-induced neuronal cell death through glucose-in-
duced superoxide production and glucose-induced mito-
chondrial hyperpolarization (83). Recently, the “uncoupling
to survive” hypothesis was suggested by the positive correla-
tion between metabolic rate and life span across many
species (78). ROS production induced by oligomycin was
significantly ( p < 0.05) reduced in ketogenic diet-fed mice
compared to ad libitum controls, suggesting that a ketogenic
diet may have neuroprotective effects by diminishing ROS
production through activation of mitochondrial UCPs (80),
although the effects of ketogenesis on metabolism are quite
complex, and include modulation of insulin signaling.
CONCLUSION AND PERSPECTIVES
UCPs are normally expressed in brain and regulated by
CNS injury in affected brain regions, where they are postulated
to cause mild uncoupling, reducing electron leakage from the
electron transport chain, and thereby decrease superoxide gen-
eration. Mitochondrial ROS generation in pathological condi-
tions is dependent on mitochondrial membrane potential, and
despite a number of questions that remain to be answered, evi-
dence suggests that overexpression of UCPs can be neuropro-
tective. However, in some situations, UCP activation may result
in a balance between beneficial and detrimental effects. UCP
expression can be proapoptotic, as well as antiapoptotic, de-
pending on transcriptional and biochemical regulation (20, 60).
Mitochondrial membrane potential is the main regulator
of mitochondria Ca2+ uptake, and many Ca2+-dependent path-
ways are involved in neuronal cell death. Understanding the
role of mild uncoupling in Ca2+ homeostasis and mitochon-
drial free radical generation in excitotoxicity may help our
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understanding of a key mechanism of neurotoxicity (64). Finally,
overexpression of UCP results in growth inhibition in yeast (3,
74), an effect that may be related not only to changes in energy
metabolism such as reduced ATP production, but may also re-
flect dysregulation of redox-sensitive pathways, including ac-
tivation of mitogen-activating protein kinase signaling.
The idea that this is due to modification of mitochondrial
ROS production places these proteins in the intriguing posi-
tion of integrating both metabolic function and oxidative
stress. Although it is suggested that modification of UCPs
can lead to many other cellular responses, including changes
in antioxidant defense systems and mitochondrial biogenesis,
careful investigation will be needed to identify the detailed
mechanisms behind their neuroprotective effects. Elucidating
the mechanism(s) of UCP action in the regulation of energy
metabolism and ROS generation would advance our under-
standing of how cells regulate their “power plants” to respond
to normal physiology and stress conditions.
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